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430 Resulfs: Followlng stant opllmlzfltion: 
El 902 3 Serum Amylold Protein A: Detectlon In Human Atheroeclerotlc Lealone and Assoclatlon Wlth Acute 
Coronary Syndromes 
,I. Krournr, K. Suchar, I? Salbach, L. .Inhn, W. KOblor. /nna@ Modlrh III, 
Un~vewll#f Heldelbe~, ffaldalbsrg, Qatmnny 
Tha ncutq pharm prutaln nflrum nmylold A (SAA) hna boon tlhown lo be 
nlqvatsd In rtoutn myocnrdlnl Inlnmllan nnd unalnbls analnn, The pnllanta 
with unstnbln nnglnn who hnd lha hlghast SAA lavale, had R algnlllcanlly 
higher rlak for the dovnlopmon~ nf myoaNdlAl InlamXan, MOIQ rocanlly aculo 
phnss problns hnvs nl8a baan Impllan~ad In tha pro$jrosa of nlharoaclamsls, 
It lhua wan ot Intsrsnt 10 aludy depofllllon ot SAA In athsmsclam~lc laslonn. 
Speclmon tram 41 canaooullva coronnly n~haruotomlssr (22 pntlanla wllh 
unalable, 10 with fdablo anglna) wt-tro InvesNyrdad lar \ha pmaance al SAA 
by Immunacytqchamlahy. Ualng anllbodlss dlma~ad ngalna( SAA, n.natin, 
ven WIllsbrand tnclar and Mnc.1 asm~quqnlltnllon nnd Iocnllra~lan 01 SAA 
Immunnmactlvlty was portarmod, 
38 01 ths 8paclman could ba nnnlyrad. Tho nmaunl al BAA Imrnunam~ 
~atlvlly wan gradad 0, 1 ar 2 by two lndnpondanl bltndad Invaallgatom. SAA 
RCORB w@m lhnn oormldad to pnllanls cllnlcnl symptoms, Pntlonh! wllh RIR, 
bls Anglnn ht#d R SAA.plt?qus acaro al 0.R 1 0.70 fla oppoaad to 1 ,l 1 0.71 
lor ptdlqnta with unatabla anglnn (p - 0.05). Immunamnollvlly colocnkxod 
pmdamlnrdaly ta amrmth muacla aslle, hawavor. was nlao lound In close 
pmxlmlty )a monmyloa and andothallnl calls. 
It hna been damonalratad In vllm lhnt SAA can land ta manrxyta mlgrallan 
and astlvatlan. Thua It 19 hypathaslrod lhat SAA locallead In the nrtanoscla. 
mtlc lallan InndR lo dtxdnblllXn~lon nnd aubaaquonl ruplum al tho plnquo ns 
wall RI pmgmaa at tho nlhoro8ctomtlo loalan. 
4:45 
Elevated Serum Homoc stelne: Revsrslble Risk 
Factor In Patlents Wlth E oronary Vaaospaam 
Homocystalno (Hey) Is n mombollto al molhlanlno wtlh nrlhom~onlc propar. 
llas vln csndolhollnl ctyatunctlon. Wo oxomrnod tha rulntlonshtpa botwonn lho 
dsk at pallonts wlth coronary vnsasposm and sonrm total Hey. folato. vitamin 
012 and pliinma vllomln Eil2. 
M@tf?r?&: Fnstlng sorum ticy. lolnto nnd vtlnmln Et12 and plnsma vita- 
mln R6 conmnlmllans warn datonlnad In 20 pntionls (6 mon, 12 womon. 
age 52.7 ! 12.2) wlth coronruy vnsospnsm. which wore domonstmtod by 
camnnry nnglogmphlcnlly local vasospnsm wllh angina. wem compamd wtlh 
honlthy aga and aex-matched contmr (6 mon and 7 womon. age 51.9 -t 12.5) 
f?osub: Moan sonrm Hey conconlrntlon was higher in case group lhan 
contml (15.0 t 1 1 vs 10.9 I 1 3 jrmol/L, p = 002). Sorum tolato (6.5 t 
0.9 vs 96 i 0.9 ngk. p 3 0.02)) vitamin 012 (534.4 i 59.6 vs. 636.6 t 
64.2 pmt.. p = 0 007’) and plnsmn vl~amln B6 (75.7 i 10.9 vs. 126.9 t t 3.0 
m&l., p EI 0.033) worn slgnllicantly lowor In case group lhan control. 
Cun&.sron: Thoso datn support the hypothesis that olovatod sorum Hcy 
is a dsk laoloi In patlonts wllh cornnary vasospasm and low lolalo, vitamin 
Et12 nnd vltamln Et6 may account lor olovatod homrxystoln Ievol. Smco 
homocystolno can bo mducod by admmlstraion 01 lolalo and vitamin 812. a 
posslblo thompoutrc mlo for thoso agonts may oxrst in patronts with coronary 
vnsospasm. 
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903-l CRUISE: Can Routine Intravascular Ultrasound 
lntluence Stent Expansion? Analysis of Outcomes 
P.J. Fitzgerald. M. Hayaso. G.S. Minlz, R. Kuntz. J.W. Moses. D.J. Diver. 
E. DouIsch. CA. Simonton. D.S. Bairn. M.B. Leon, P.G. Yock. For fhe 
CRUISE Investigatoffi; Sdord UniversiIy Medical Cenfer CA. USA 
CRUISE. the lVUS substudy of tho STAPStrial. was designed to inoasure the 
impact of IVUS guidance on stont deployment in the high-pressum era. Ten 
CenlOffi were pmspectively assigned to stent deployment using ultrasound 
guidance (UG) and 7 to angiographic guidance alone (AG) with blinded IVUS 
at the end al the procedure. A total of 539 cases were enrolled with completed 
quantitative coronary angiography @CA). ullrasound analysis (PCU), and 
cllnical event ratOS in 499 patients. Oulcomo as assessed by target vessel 
ravascularization (TVR) was defined as clinically driven repeat PTCA or 
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Condunipn; Thaes dala tmm tho CRUISE tnat auggost that ullnaaund 
guidanca reaulls in A lsrgsr slant lumon ama ComParod to nnWgraPhr 
guidancs nlona, rosulling in n 39% rfrlabvo mducllOn In bW31 vessel rovas- 
culnriration. 
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andablo Stent Versus Balloonaxpandnbte 
Serial Volumetrla Anatyals by tntravawukw 
Ultranound 
Y. Kobayaah& PS Toiratoln, S.R. Bailey. CL. Brown. 111. L.G. Chnslro. 
R.V. Mallhows, R.S. Schwartz. A.C. 00 Franco. C.E. Handen, P.G. Yo&. 
P J Frlrgorald. Skmlon-l Unc~?rsrR! StanfortI CA. USA 
Ta evaluate noomtrmnl prolitoratron and chrunrc slcnt rml m a sotl-expand- 
abla stont (SE. RADIUS’) and a batloon-oxpandabte stent (BE. Palmar- 
Schatr”), 91 patronts lmm hvo centora woro enterod into the intravascutar ul- 
lrasound (IVUS) aubstudy 01 lhe SCORES (Stent COmparattvo RESterrqs~) 
tnnl IVUS soans wnm p~%Iomwd in each pattent lollowmg stent M 
and at B-month tallow-up (I/u). To date, sonal votumelric data are avarlabte 
(or the first 20 patronts (SE: 9. BE: 12) campletmg lfu (184 f 27 days). 
R~ulfs: SE stents increased 20.2% rn cross secttonal area and 0uoraN 
valumo (121.9 -t 36.3 mm3 to 146.5 t 47.7 mm>, p -: 0.01). tioweuer. m 
BE stonts. no signilrcanl change in overall area or v&one was observed 
(144 2 i 62.8 mm3 ta 136.4 t 62.2 mmJ. p = ns). In addrtron. no s~gnrficant 
dittamnco m neolntlmat valumo tndox (neomtrmal vulurn&tent voturr’m at t/u) 
was observed bstwoen Ihe two groups (32.9 f 24.0% rn SE. 21.6 2 16.00. rn 
BE. p c ns). In oath group. the mmimum lumen area decreased s~gmlrcanlly 
aver trme. howovor. SE stonts trended (not stahstlcally srgmkant) to have 
loss lalo lumen toss (6.70 t 1.19 mm: to 4.94 i 2.57 mm*. lata lumen loss. 
1 76 i 2.29 mm’) compared lo BE stents (7.29 t 2 24 mm* to 4.32 r 1 52 
mm”. lato lumen loss. 2 9i t 2.57 mm”) 
Conclusrons: These prekmrnary results suggest that SE stonts mcrease 
In overall slzo wrthln 6.month t/u perrod. have mtlmal pmklerahon 51rnrlar to 
that 01 BE stonts and trend lowards smaller late lumen loss 
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1903-3 1 Restenosls Atter Coronary Stentlng Guided by 
Intracomnary Doppler Flow Velocity Reserve 
Measurements 
M Haudo. 0. Baumgart. G. Caspan. 0. Wolge. J. Ge. F LIU. R Erbot. 
Cardrology &partment. Untverscty Essen. Germany 
Background: Coronary flow velocity ratro (CVR) assessed by intracoronary 
Doppler ttuide wares (Cardrometncs. Mountain Vrow. USA) allows to estrmate 
the lunctronal result of a coronary mterventron. 
Meethods: Instead 01 usmg a general cut-oft value lor CVR (--2.5 in the 
DEBATE I tnal) wo gurded the stenl procedure by the Individual measuro- 
mont of CVR in a non-stonotic rolorence artery. To evaluate the Impact of 
this strategy on the occurrence of restenoas (-50% diameter stenosrs). we 
measured CVR drstal to the target lesion (CVRd) and in a reference vessel 
(CVRrel) in 50 patients (pls) with LAD stenoses. Measurements were re- 
peated after PTCA. after stentrng. and atter 6 monlhs. CVR was calculated 
as the ratio of hyperemic (19 rig adenosine ic) and baseline flow vf?locity Ad- 
ditionally quantitative coronary angiography (minimal umen diamater. MILD) 
of the target lesion was performed. 
___ -~ 
Elotore Aftor Alter Aner AeStenOSIS 
PTCA PTCA stent 6 months rate 
CVR 12405 25107’ 3.1 f06§ 2.9 * 0.8 - 
CVRd ,CVArel o/50 m/50 45&O 46150 4/45 (9%) 
CVRd -2.5 O/SO 22i50 40/50 40150 E/40 1209.1 
MLD [mm] 0.9 ‘ 0.5 2.1 107 3.0 i 0.5 2.1 i 0.8 
Residual ~lonosls 0150 18150 50150 32/50 
35% 
’ p 0.01 versus belore PTCA. 5. p . 0.01 versus aner PTCA 
ffe.w!fs are shown in lhe 1aMQ. CVRrel was 3.2 * 0.7 before tntewenlton 
and 3.1 k 0.9 after 6 months. 
&nduwr Gwdence Ql CVRd by CVRrel Instead 01 fixed cti.off !ovets 




9034 Multlc#ntor Aa kin wtd Tk!c ldkto THal At&r 
lntmcwnary tenting In Hlg Rlrk Patkmtr g R 
V. h%?non. LA Sleeper. R. File, J.S. l-kxknar. For me SNOCK 
Inn?stga~ Sf. LukeH?msewn tbqwal Center. Columma Unrvwsny. 
ivewYork.NY.UsA 
Pulmonary Artery cathetenzatron (PAC) has been assonafed ~IUI mcreased 
mottakly but its use tn Caf@ogenic Shock (CS) IS w&spread. The SHOCK 
Registn/ ts a P- database Of patients wrul suspected cs folIowIng 
AM. 1-1 evalua:e L?e impact of PAC. basalme vanebb. hamadynarma and 
outcomes m 567 patients wlao recewed PAC were compared to 2S3 patients 
managed mthoul PAC. A ‘pr~+wtsity scorn’’ for PAC pkcemenl was dewed 
fmm a log&c regression model usmg baseline Mnabfes and ad@sred mor- 
Iality rates were compared. Patfffs receiving PAC were signikanHy ywnger 
(67.5 f 11.4&7#.5 f 11.6yfs. p c 0.0001). w-en? more likefytobebansfera 
(46% vs 27%. p < 0.0001). had less prior MI (35 vs 48%. p = 0.0081 and 
developed CS later (7.8 vs 4.5 median hrs. p = 0.005). Atthough lowesl SBP 
(69 f 18 vs 69 f 19 mm. p = 0.816) and MI location were similar. pabents 
wxvlth PAC had increased HR (99 i 25 vs 69 i 28. p = 0.0001). SBP (92 * 21 
w77*20mm.p=~0.0001)and08P(55*15vs45r.20mm.p=0.0001) 
with more inotrope use and were more likely to undergo calh. PTCA. IABP 
and CABG (p < 0.0001) with decreased In hospllal mortality (56 vs 79%. p 
< 0.0001) bul no impact on LOS. Even after adfuslmg for baseline vanables 
(PAC pmpenstty) patients receiving PAC had lowered mortality (OR 0.458 
95% Cl 0.31-0.67. Chi-square 15.4, p = 0.0001). 
Conclusion: PAC use in suspected CS is associated with aggressive 
therapy and a lower in hospital mortality. Selection bias is ewdent but no 
harm associated with PAC was demonstrated. 
m] 
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Aueument o? P~tentlal lot Weaning From 
MechanIcal left Vontrkubr Support U~lng 
Qwmtltatlve Echocardlogmphy 
shock m 1. and penpanum caa 
5. AM 4 T:<mtec 2. end NC facor 1 
~vinl.LVADe@aced:@&med&s 
D~~~~IcuI of suppod was lb * 21 
days. Meapu~?a ot mt&LV Mart aws Wi ares (EDAJ. v 
erea @?iAJ. ind hactwnal ar8il chcnca [FAC = (EDA - ESAlEDA) were 
me& dunng n@ LVAD fiow: 4.6 f 0.4 f&m and wnoy weanmg to h 
LVAD lbv. 1.9 + 0 9 Umin. jeven p(e had ~ucces~tul refnwal 01 LVAD 
(mchrdmg Ttwetec mwxnd in 1) and euwiverl lo ho-1 dtshatge. Five 
pts remelnad LVAD dependent. 4 dted vtthrn 7 days, 1 was hasrpfantad. 
Easekne LV FAC dO% w I tv&mvamt m LV FAC % J ~20% frmn hgh 
to low LVAD tlwr was predIctbe ot successful LVAD racnoval (p c 0.05). All 
LVADdependenfpt~cwMnofwtcmase FAC > 15% WIWI low LVAD Ilow 
w 0 Lv1D(lrwnlomap + 
l rv~-arovo 1 
Conctmm Ownmaiwe echo may be useful to assess myocardfal re- 
covery II-I ph on LVAD s+rpporl and aid m me ckmcal denson Ior LVAD 
removal. 
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L-J 904 3 Gender and other Pmdk%om of kvtraaortlc Balloon 
Pump Complications: Pmspectiv8 Study of t ,t t 9 
a&m& Patients at Single High Volume, Tertiary 
MS. Dawsan C K-y. R. McBride. M. Cohen. Anegheny unrversrfy 
ot me Health Sciences. Pfnl&?@lna PA. USA 
Backgrcund This p-e study exammed me c~mpl~catkms a zxxtated 
wnfh mntraaorl~c baflcun (IAB) counterpulsahon and the rofe of gender an the 
current em 
AeModp:Weevafuafed1.119~ percutaneovs IAB msedmns 
al Allegheny Umvefstty H-5. Hafmemann Dtwston from January 1993 
to June 1997 All patients were followed prospectiily Wcm a deify cllntcal 
evafuabon. M-r compkcatkms were defmed as balloon niplure. emboksm 
or kmb rsthemfa reqlnnng surgery. bleedtng requtnng transtunon. sysmmif 
Wection. or deam due to one of the above. 
ResuIfs There were 727 men and 392 women (age, 65 L 11 yrs.). 
~nctdence of cfiabates (27%). hypertension (52%). or penphafal v scular 
disease (8%) A total of 196 compfiiti~ns axwed and a map compke?km 
occurred m 126 ot 1,119 pallems (119b). Mutioaro logrsllc rcgressmn 
analysts ot age. cardtac Mex. b&y surface area (BSA). gender, diabetes 
and penpheal vasculaf disease (PVD) as covanates. ideWed PVD (felattve 
risk. RR = 4.1). female gender (RR = 2 3). and BSA (RR - 0.26 per m2) 
as Mependent predictors 01 a mafor compllcatlon. Defmlng ‘high risk”.. as 
women or pabents with BSA < 1.8 mZ. cardiac index -.2.2. dtabatas Or PVD. 
predicted 150 compllcattons smong 818 patter@. (18%) compared to 16 
complications among 301 ‘low risk’ patients (5%) (p -Z 0.0001). 
Conclunon: Despite reducficns in sizes of IAB and sheath. the cun-enl 
complication rare associated with mbaaortii counterpulsat!on remains high. 
Advances in IAB technology need to focus on Ihe ‘high risk’ Subset Of Pabents 
that incluti wor+,.l. or smaller pattents. and those tih PVD. 
